Compare EYPT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYPT | ANAB |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | 2015 |
| Metric | EYPT | ANAB |
|---|---|---|
| Price | $12.86 | $62.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $31.80 | ★ $72.60 |
| AVG Volume (30 Days) | ★ 1.2M | 491.1K |
| Earning Date | 03-04-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,031.72 | $33.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $3.91 | $15.40 |
| 52 Week High | $19.11 | $68.39 |
| Indicator | EYPT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 58.31 |
| Support Level | $12.05 | $43.67 |
| Resistance Level | $13.32 | N/A |
| Average True Range (ATR) | 1.01 | 4.10 |
| MACD | -0.33 | -0.07 |
| Stochastic Oscillator | 3.45 | 63.00 |
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).